- 05 Sep 2024
- ICICI Securities
NATCO INVESTS IN BIOTECHNOLOGY COMPANY
News: Natco plans to invest USD 8 million(Rs 67 crore) in eGenesis, Inc. to acquire 4,06,29,761 shares, eGenesis is a biotech company pioneering in xenotransplantation with focus on developing safe and effective human compatible organs for transplant.
Views: eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant. The investment. albeit small could open up another niche area for Natco in future.
Impact: Positive